Connect with us

Technology

SandboxAQ Partners with The Michael J. Fox Foundation for Parkinson’s Research in $25 Million Initiative to Develop Novel Treatments

Published

2 months ago

on

SandboxAQ collaborating with the University of Dundee through The Michael J. Fox Foundation’s LRRK2 Investigative Therapeutics Exchange (LITE) program to improve its inhibitor for the gene most commonly associated with Parkinson’s

PALO ALTO, Calif., Oct. 29, 2024 /PRNewswire/ — SandboxAQ announced today it has signed a $25 million research grant through The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program to advance drug candidates for Parkinson’s disease (PD.) The partnership brings SandboxAQ’s expertise in neurodegenerative diseases and its Large Quantitative Models (LQMs) to cutting-edge research in the field of Parkinson’s research where, despite important biological and genetic discoveries, effective new therapeutics have yet to be approved.

As part of the partnership, SandboxAQ will collaborate with University of Dundee in Scotland to improve the potency and specificity of its LRRK2 inhibitors and to identify innovative compounds acting as allosteric modulators. LRRK2 is a gene identified in 2004 as being the most commonly associated with Parkinson’s, however, no new therapy targeting this protein has reached the market.

This research grant is to support an MJFF program focused on bridging basic science advances to industry-led drug development. LITE will include tens of millions of dollars in grant support and has already attracted more than 30 academic and clinical collaborators and more than a dozen companies. The program aims to develop new approaches to targeting the LRRK2 gene with therapies while also supporting the development of LRRK2-relevant clinical biomarkers to measure progress.

The initiative will take advantage of recent LRRK2 structures to identify or design new drug candidate molecules and complete pre-clinical investigation, with the goal of optimizing four inhibitors with distinct modes of action within the next two years. The agreement includes a license for SandboxAQ’s LQMs, with key milestones to be delivered over the 24-month engagement period.

“By combining MJFF’s network and expertise with SandboxAQ’s AI and computational capabilities, we have a powerful force joining us and creating a unique opportunity to accelerate the development of new therapies for Parkinson’s,” said Professor Dario Alessi, Director of the MRC Protein Phosphorylation Unit at the University of Dundee and LITE program leader. “This collaboration represents a significant step forward in our understanding and treatment of this challenging disease.”

SandboxAQ’s LQMs integrate AI tools with physics-based scoring functions, allowing the creation of detailed protein-ligand complex models, the rapid screening of millions of compounds, ligand identification, and small molecule design.

These technologies will help advance the research being conducted across the LITE Consortium, whose projects are led by scientists from the University of Dundee and attract more than 30 global academic and clinical collaborators as well as more than a dozen companies. SandboxAQ is one of the first commercial partners to join the LITE consortium.

“We are confident that SandboxAQ’s Large Quantitative Models and AI simulation techniques will enable us to translate academic discoveries into new drugs and ultimately help people who have Parkinson’s disease,” said Nadia Harhen, GM of AI Simulation at SandboxAQ. “Our partners at the University of Dundee have done extraordinarily important preclinical research, and we are excited to help them translate their discoveries into breakthrough therapies to help patients affected by PD.”

The collaboration with the University of Dundee is SandboxAQ’s second research partnership with the MJFF. Also today, SandboxAQ shared a collaboration with Belgium-based KU Leuven‘s Vangheluwe Lab to identify small molecule modulators capable of restoring the function of the ATP10B gene, another key gene linked to PD.

About SandboxAQ
‍SandboxAQ is a B2B company delivering AI solutions that address some of the world’s greatest challenges. The company’s Large Quantitative Models (LQMs) deliver critical advances in life sciences, financial services, navigation, cyber and other sectors. The company emerged from Alphabet Inc. as an independent, growth capital-backed company in 2022, funded by leading investors including T. Rowe Price, Eric Schmidt, Breyer Capital, Guggenheim Partners, Marc Benioff, Thomas Tull, Section32, and others. For more information, visit http://www.sandboxaq.com.

About the LRRK2 Investigative Therapeutics Exchange (LITE) Program
The Michael J. Fox Foundation for Parkinson’s Research launched LITE in 2024 to support new approaches to targeting the LRRK2 gene with therapies, while also supporting the development of LRRK2-relevant clinical biomarkers to measure progress. Mutations in the LRRK2 gene were first linked to PD 20 years ago, and they are now understood to be the most common causes of inherited PD. The LITE program, which will provide tens of millions of dollars of grant support, paves the way for new cooperation on LRRK2, attracting more than 30 academic and clinical collaborators as well as more than a dozen companies expressing interest at launch. The program connects companies that are developing LRRK2-targeting therapies with key opinion leaders and provides preclinical and clinical resources to establish best practices for advancing LRRK2 therapeutics. LITE will be led by Dario Alessi, PhD, of the University of Dundee in the United Kingdom. Alessi, a global leader in the study of kinases, leads a project focusing on LRRK2 signaling pathways as part of the Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network (CRN), creating a point of collaboration across initiatives as he continues to build on this work in the space. The LITE program also will benefit from collaboration with other ASAP initiative-supported programs including the Parkinson’s Progression Markers Initiatives (PPMI) and the Global Parkinson’s Genetics Program (GP2). Learn more here.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sandboxaq-partners-with-the-michael-j-fox-foundation-for-parkinsons-research-in-25-million-initiative-to-develop-novel-treatments-302290452.html

SOURCE SandboxAQ

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

OceanBase Receives Honorable Mention for the Second Consecutive Year in the 2024 Gartner® Magic Quadrant™ Report

Published

11 minutes ago

on

December 26, 2024

By

SINGAPORE, Dec. 26, 2024 /PRNewswire/ — OceanBase has once again been named as Honorable Mention in the 2024 Gartner® Magic Quadrant™ for Cloud Database Management Systems (Cloud DBMS), marking the second consecutive year it has received this recognition.

OceanBase offers scalable distributed database for data-intensive transactional and real-time operational analytics workloads, with ultra-fast performance and high compatibility across major global cloud infrastructures, including Amazon Web Services, Google Cloud, Alibaba Cloud and Tencent Cloud. Operating across more than 30 regions in Asia, Europe, and America, OceanBase has already served over 2,000 customers, such as SAIC Volkswagen, DiDi Global, vivo, Pop Mart, Haidilao, Kwai, Trip.com, GCash, DANA, and PalmPay.

Over the past year, OceanBase has made significant strides in the Southeast Asian market. In December 2024, Starpay, a leading financial technology company in the Philippines, announced a partnership with OceanBase to leverage its cutting-edge distributed database solutions.

OceanBase hosted the inaugural OceanBase INFINITY tech conference in Jakarta, Indonesia in June 2024. During the event, the company announced strategic partnerships with leading local resellers to better serve customers in the Indonesian market.

According to Gartner’s latest DBMS market data in the Magic Quadrant, “the overall database management system market grew by 13.4% in 2023, reaching $103.2 billion“, up from $91 billion in 2022. The DBMS segment remains one of the fastest-growing areas within the software market, alongside analytic platforms, networking software, and supply chain management software.

In May 2024, OceanBase was also recognized as an Asia/Pacific Customers’ Choice and also named a Strong Performer in the 2024 Gartner® Peer Insights™ Voice of the Customer for Cloud DBMS report.

Gartner, Magic Quadrant for Cloud Database Management Systems, 18 December 2024

Gartner, Voice of the Customer for Cloud Database Management Systems, 24 May 2024

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

GARTNER, MGAGIC QUADRANT and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

About OceanBase

OceanBase is a distributed database launched in 2010. It provides strong data consistency, high availability, high performance, cost efficiency, elastic scalability, and compatibility with mainstream relational databases. It handles transactional, analytical, and AI workloads through a unified data engine, enabling mission-critical applications and real-time analytics.

To learn more, please visit: https://www.oceanbase.com/

View original content:https://www.prnewswire.com/apac/news-releases/oceanbase-receives-honorable-mention-for-the-second-consecutive-year-in-the-2024-gartner-magic-quadrant-report-302339146.html

SOURCE OceanBase

Continue Reading

Technology

Matwings Technology Raised Series A Funding of Tens of Millions USD to Redefine Protein Design

Published

11 minutes ago

on

December 26, 2024

By

‘Beyond Structure, Predicting Function’

SHANGHAI, Dec. 25, 2024 /PRNewswire/ — Recently, Shanghai Matwings Technology Co., Ltd. (‘Matwings’), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qiming Venture Partners.

Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein™, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein™ offers a new approach for acquiring high-functioning proteins.

AccelProtein™ is built on the Pro-PRIME model, a breakthrough developed by a collaborative team led by Professor Liang Hong at Shanghai Jiao Tong University. After years of research focused on data collection, curation, and optimization, the team developed the Pro-series – an AI framework for protein design. Their work, titled “A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity” was recently published in Science Advances.

A featured case of AccelProtein™’s impact is the design of a specialized Glycosyltransferase enzyme, which is used in the production of EPS-G7, a core material for pancreatitis screening. Within just 4 months, Matwings increased the enzyme’s total glycosylation activity by 7 times, enhanced product specificity from 60% to 98%, and reduced hydrolytic activity by 33%. These improvements cut down the cost of EPS-G7 by 90%.

In another application, Matwings successfully engineered a super alkali-resistant affinity ligand (a nanobody) for affinity chromatography, improving alkali resistance by 3 folds, binding capacity over 100%, and heat stability by 8℃. This innovation saved millions of USD in CMC costs for a Matwings client. Additionally, scale-up production to 5000L has been successfully completed. Such advancement enables low-cost affinity chromatography purification a viable option for a wide range of biologics, bringing more cost-effective solutions for drug production.

Since 2021, Matwings has successfully delivered over 30 protein-engineering and enzyme-mining projects either proprietary (e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and phi29 DNA Polymerase) and co-developed with our stakeholders. These projects span across various applications, including drug innovation, in vitro diagnostics, nutrition and healthcare, food and beverage, and green energy.

About Matwings

Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University, is one of the earliest companies to focus on AI protein models.

Matwings is dedicated to moving beyond directed evolution methods to design and engineer functionally optimized proteins by leveraging a proprietary, pre-trained, AI-based general protein design platform with 780 million curated full-length protein sequence data, including nearly 500 million private data.

This cutting-edge technology platform, AccelProtein™, enables us to engineer proteins and uncover or de novo design novel proteins with significantly improved properties, including stability, activity, affinity, yield, etc.

To date, Matwings has successfully engineered more than 30 proteins either proprietary or co-developed with its stakeholders, and more than 40 ongoing projects across various applications in pharmaceutical industries and synthetic biology industries, e.g.  key enzymes and proteins for CMC, innovative Biologics, synthetic biology and more.

Matwings is actively seeking global partnerships to jointly develop and commercialize new products.

Contact Information:
Email: info@matwings.com
Website: https://www.matwings.com/en/ 
Tel: +86 158 2106 5410
Paper Link: https://www.science.org/doi/10.1126/sciadv.adr2641 

View original content:https://www.prnewswire.com/news-releases/matwings-technology-raised-series-a-funding-of-tens-of-millions-usd-to-redefine-protein-design-302339150.html

SOURCE Matwings Technology

Continue Reading

Technology

Agoda Highlights Tokyo as Top Global New Year’s Eve Destination

Published

1 hour ago

on

December 26, 2024

By

SINGAPORE, Dec. 26, 2024 /PRNewswire/ — Digital travel platform Agoda has announced Tokyo as the most popular destination for New Year’s Eve, based on accommodation searches. This marks a shift from last year when Taipei held the top spot. Following Tokyo, the list includes Bangkok, Taipei, Pattaya, and Osaka, showcasing a diverse range of preferences among travelers.

The data highlights a perpetual interest in Tokyo, a city known for its unique blend of tradition and modernity. Travelers are drawn to its vibrant celebrations, cultural experiences, and iconic landmarks. Bangkok and Taipei, too, continue to be favored destinations, offering rich cultural festivities and lively atmospheres. Pattaya and Osaka also make the list, appealing to those seeking beachside celebrations and culinary delights, respectively.

Agoda’s data reveals Tokyo’s prominence not only on a worldwide scale but also within Japan. Domestic accommodation searches have increased by 23%, with Tokyo leading as the preferred destination, followed by Osaka, Kyoto, Yokohama, and Okinawa Main Island. For Japanese traveling abroad, the destinations primarily considered are Taipei, Seoul, Bangkok, Pattaya, and Hong Kong.

Hiroto Ooka, Associate Vice President North Asia at Agoda said: “Tokyo’s rise to the top of Agoda’s New Year’s Eve destination list is a testament to the city’s global appeal. Whether you’re celebrating New Year’s Eve in Tokyo, Osaka, or anywhere else in the world, Agoda is ready to help you find the perfect spot to ring in the New Year.”

As travelers prepare for their New Year’s Eve plans, Agoda offers a comprehensive selection of over 4.5 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all available for seamless booking. Download the Agoda app for the latest deals or visit agoda.com/deals.

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/agoda-highlights-tokyo-as-top-global-new-years-eve-destination-302338856.html

SOURCE Agoda

Continue Reading

Trending